Quick Answer
Zenas BioPharma, Inc. reported Cash and Equivalents of $110.64 million for fiscal year 2025.
Zenas BioPharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $110.64M | -65.4% |
| 2024 | $319.74M | +462.4% |
| 2023 | $56.86M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $115.56M | -67.9% | +162.6% |
| June 30, 2025 | $44.01M | -76.1% | -77.6% |
| March 31, 2025 | $196.55M | +429.0% | -38.5% |
| December 31, 2024 | $319.74M | +462.4% | -11.2% |
| September 30, 2024 | $360.04M | +397.9% | +95.7% |
| June 30, 2024 | $183.93M | — | +395.0% |
| March 31, 2024 | $37.15M | — | -34.7% |
| December 31, 2023 | $56.86M | — | -21.4% |
- Zenas BioPharma, Inc. showed a decrease of -65.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Zenas BioPharma, Inc.’s cash and equivalents has grown by 94.6% (from $56.86 million to $110.64 million).
- The most recent figure is from Zenas BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: